May 9, 2023
Amicogen-Lysando partnership to tackle mastitis in dairy cows
Amicogen, a biotech company focusing on industrial enzyme production and drug development, has teamed up with Lysando, which has a background in the development of antimicrobial Artilysin, to address the increasing issue of mastitis in dairy cows caused by multi-resistant bacteria.
A company release cited that the overuse of antibiotics in animal husbandry has been causing a rapid increase in multidrug-resistant pathogens. About 70% of all antibiotics produced around the world are used in agriculture, often as preventative measures, which has advanced the spread of resistances.
Amicogen and Lysando are maximising their combined expertise to create an innovative treatment that is effective and sustainable, reducing the economic impact of mastitis on farmers while enhancing animal welfare.
"We are excited to partner with Lysando to develop a novel and innovative solution against mastitis in dairy cows," said Dr. Park, chief executive officer of Amicogen, in the release. "This collaboration highlights the growing importance of joining forces in biotech and the potential for innovation to address critical challenges – also in agriculture."
"Our Artilysin technology has shown great promise in addressing bacterial infections and we believe that this partnership will make a real difference in the fight against mastitis," said Kerstin Emmrich, R&D director at Lysando AG.